1 EXHIBIT 10.38 AMENDMENT NO. 1 TO IFN-G DISTRIBUTION AGREEMENT This AMENDMENT NO. 1 ("Amendment") is entered into as of this the 4th day of April, 2000, by and between AMARILLO BIOSCIENCES, INC., a Texas corporation with its principal place of...Distribution Agreement • April 16th, 2001 • Amarillo Biosciences Inc • Pharmaceutical preparations
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 15th, 2008 • Amarillo Biosciences Inc • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 8, 2008 between Amarillo Biosciences, Inc., a Texas corporation (the “Company”) and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
1 LICENSE AGREEMENT BETWEEN ATRIX LABORATORIES, INC. AND AMARILLO BIOSCIENCES, INC. SEPTEMBER 7, 2001License Agreement • September 24th, 2001 • Amarillo Biosciences Inc • Pharmaceutical preparations • Delaware
Exhibit 10.45 SUPPLY AGREEMENT THIS AGREEMENT is entered into this 10th day of June 2004, by and between Jerry Frasier at Global Kinetics, Inc., 4628 Kent Court, Kent, Washington 98032 (herein referred to as "GLOBAL") and Amarillo Biosciences, Inc., a...Supply Agreement • April 15th, 2005 • Amarillo Biosciences Inc • Pharmaceutical preparations • Texas
1 EXHIBIT 10.27 DISTRIBUTION AGREEMENT THIS DISTRIBUTION AGREEMENT ("Agreement") is made and effective this 12th day of January, 1998, by and between AMARILLO BIOSCIENCES, INC., a Texas corporation with its principal place of business at 800 W. 9th,...Distribution Agreement • March 30th, 1998 • Amarillo Biosciences Inc • Pharmaceutical preparations
1 EXHIBIT 10.30 AMENDMENT NO. 1 TO LICENSE AGREEMENT OF MARCH 22, 1988 BETWEEN AMARILLO BIOSCIENCES, INC. AND THE TEXAS A&M UNIVERSITY SYSTEM THIS AMENDMENT NO. 1 ("Amendment") is entered into as of this the ____ day of __________________, 1998, by...License Agreement • March 30th, 1999 • Amarillo Biosciences Inc • Pharmaceutical preparations
SERIES A COMMON STOCK PURCHASE WARRANT AMARILLO BIOSCIENCES, INC.Amarillo Biosciences Inc • January 15th, 2008 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the earlier of December ___, 2012 anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Amarillo Biosciences, Inc., a Texas corporation (the “Company”), up to ______ shares (the “Warrant Shares”) of common stock, par value $.01 per share (the “Common Stock”), of the Company. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT AINOS, INC.Common Stock Purchase Warrant • August 12th, 2022 • Ainos, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cede & Co. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 11, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Ainos, Inc., a company incorporated under the laws of the State of Texas (the “Company”), up to 897,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warran
ARTICLE IEmployment Contract • March 30th, 1999 • Amarillo Biosciences Inc • Pharmaceutical preparations
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 22nd, 2008 • Amarillo Biosciences Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 8, 2008, Amarillo Biosciences, Inc, a Texas corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AINOS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY, as Warrant Agent Warrant Agency Agreement Dated as of August 11, 2022 WARRANT AGENCY AGREEMENTWarrant Agency Agreement • August 12th, 2022 • Ainos, Inc. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of August 11, 2022 (“Agreement”), between Ainos, Inc., a corporation organized under the laws of the State of Texas (the “Company”), and American Stock Transfer & Trust Company (the “Warrant Agent”).
PLACEMENT AGENT WARRANT AINOS, INC.Ainos, Inc. • September 29th, 2023 • Pharmaceutical preparations
THIS PLACEMENT AGENT WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [Maxim Group LLC/Brookline], or its assigns (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after __________, 2024 (the “Initial Exercise Date”) and prior to 5:00 p.m. (New York time) on ___________, 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from AINOS, INC., a Texas corporation (the “Company”), ______ shares of common stock, par value $0.01 per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
6. AUTHORITY AND CAPACITY: Wilke is not an employee of ABI and agrees to conduct all of its business in its own name as an independent contractor except where Wilke's name is listed as an agent for ABI.Sales Agreement • April 16th, 2001 • Amarillo Biosciences Inc • Pharmaceutical preparations • Kansas
1 EXHIBIT 10.35 LICENSE AGREEMENT THIS LICENSE AGREEMENT ("Agreement") is made and effective this 16th day of June, 1999, by and between AMARILLO BIOSCIENCES, INC., a Texas corporation with its principal place of business at 800 W. 9th, Amarillo,...License Agreement • September 13th, 1999 • Amarillo Biosciences Inc • Pharmaceutical preparations
License Agreement, dated as of July 22, 1997, between Amarillo Biosciences, Inc., a Texas corporation with offices at 800 West Ninth Avenue, Amarillo, Texas 79101-3206 ("ABI"), and Hoffmann-La Roche Inc., a New Jersey corporation with offices at 340...License Agreement • March 30th, 1998 • Amarillo Biosciences Inc • Pharmaceutical preparations • New Jersey
LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • April 3rd, 2006 • Amarillo Biosciences Inc • Pharmaceutical preparations • Texas
1 EXHIBIT 10.28 DISTRIBUTION AGREEMENT: TNF-A: HUMAN, ORAL AND TOPICAL; OTHER SPECIES, ALL ROUTES THIS AGREEMENT is made and effective this 17th day of September, 1997, by and between AMARILLO BIOSCIENCES, INC., a Texas corporation with its principal...Distribution Agreement • March 30th, 1998 • Amarillo Biosciences Inc • Pharmaceutical preparations
ContractAinos, Inc. • September 29th, 2023 • Pharmaceutical preparations • Delaware
THIS NOTE HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 29th, 2023 • Ainos, Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of September 25, 2023, by and between Ainos, Inc., a Texas corporation (the “Company”), and Lind Global Fund II LP, a Delaware limited partnership (the “Investor”).
ContractCommon Stock Purchase Warrant • September 29th, 2023 • Ainos, Inc. • Pharmaceutical preparations
THIS WARRANT HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
SECURITY AGREEMENTSecurity Agreement • September 29th, 2023 • Ainos, Inc. • Pharmaceutical preparations
SECURITY AGREEMENT (this "Agreement"), dated as of September 28, 2023, by and between AINOS, INC., a Texas corporation (the "Company") and LIND GLOBAL FUND II LP, a Delaware limited partnership (the "Secured Party").
AINOS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 12th, 2022 • Ainos, Inc. • Pharmaceutical preparations • New York
The undersigned, Ainos, Inc., a Texas corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”) an aggregate of 780,000 units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional 117,000 Option Shares (as defined herein and collectively with the shares of Common Stock underlying the Firm Units, the “Shares”), and/or up to an additional 117,000 Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one share of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and one Warrant. Each Warrant entitles the holder to purchase one share of Common St
1 EXHIBIT 10.36 AGREEMENT TO CONVERT DEBT THIS AGREEMENT TO CONVERT DEBT ("Agreement") is entered into as of this the 30th day of September, 1999, by and between AMARILLO BIOSCIENCES, INC., a Texas corporation ("ABI"), and HAYASHIBARA BIOCHEMICAL...Agreement • October 1st, 1999 • Amarillo Biosciences Inc • Pharmaceutical preparations
Exhibit 10.48 LICENSE AND SUPPLY AGREEMENTLicense and Supply Agreement • April 3rd, 2006 • Amarillo Biosciences Inc • Pharmaceutical preparations • Texas
1 EXHIBIT 10.43 SUPPLY AGREEMENT THIS AGREEMENT is entered into this 11 day of December, 2000, by and between Natrol, Inc., a Delaware corporation with its principal place of business in Chatsworth, California (herein referred to as "Natrol") and...Supply Agreement • April 16th, 2001 • Amarillo Biosciences Inc • Pharmaceutical preparations • California
CONVERTIBLE NOTE PURCHASE AGREEMENTConvertible Note Purchase Agreement • March 14th, 2023 • Ainos, Inc. • Pharmaceutical preparations • Texas
This Convertible Note Purchase Agreement (the “Agreement”) is made as of March 13, 2023, by and between Ainos, Inc., a Texas corporation (the “Company”), and Li-Kuo Lee (the “Purchaser”).
APPENDIX I AND II HAVE BEEN REDACTED FROM THIS AGREEMENT PURSUANT TO SEC REGULATION S-K ITEM 601(b) BECAUSE THEY ARE BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL CO- DEVELOPMENT AGREEMENTDevelopment Agreement • February 15th, 2024 • Ainos, Inc. • Pharmaceutical preparations
This co-development agreement (this “Agreement”) is made and entered into as of August 9, 2023 (the “Effective Date”), in Taiwan, by and between Nisshinbo Micro Devices Inc., having an office at 3-10, Nihonbashi Yokoyama-cho, Chuo-ku, Tokyo 103-8456, Japan (“NISD”), Ainos, Inc. having an office at 8880 Rio San Diego Drive Suite 800 San Diego, CA 92108 U.S.A. (“Ainos”) and Taiwan Inabata Sangyo Co., Ltd., having an office at 178, 2F, Sec. 2, Gongdao Wu Rd., Hsinchu City 300, Taiwan (R.O.C.) (“Inabata”), with respect to the transaction that NISD outsources the Development (as defined below) to Ainos. NISD, Ainos and Inabata are referred to individually as a “Party” and collectively as the “Parties”.
EMLOYMENT CONTRACTEmloyment Contract • March 26th, 2007 • Amarillo Biosciences Inc • Pharmaceutical preparations
This Employment Contract (“Contract”) is entered into by and between Amarillo Biosciences, Inc., a Texas corporation (“Employer”) and Martin J. Cummins (“Employee”). ABI and its controlled subsidiaries shall be hereinafter collectively referred to as “ABI Companies”. Employer hereby employs Employee, and Employee accepts employment, on the following terms and conditions.
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2021 • Amarillo Biosciences Inc • Pharmaceutical preparations • Texas
This Agreement (the "Agreement") is effective as of the 1st day of January 2021 (“Effective Date”) by and between, DR. STEPHEN T. CHEN, Ph.D. (the "EMPLOYEE"), and AMARILLO BIOSCIENCES, INC., a Texas Corporation ("EMPLOYER").
EMLOYMENT CONTRACTEmloyment Contract • March 26th, 2007 • Amarillo Biosciences Inc • Pharmaceutical preparations
This Employment Contract (“Contract”) is entered into by and between Amarillo Biosciences, Inc., a Texas corporation (“Employer”) and Gary Coy (“Employee”). ABI and its controlled subsidiaries shall be hereinafter collectively referred to as “ABI Companies”. Employer hereby employs Employee, and Employee accepts employment, on the following terms and conditions.
EMPLOYMENT AGREEMENTStock Option Agreement • August 16th, 2021 • Ainos, Inc. • Pharmaceutical preparations • California
This Agreement (the "Agreement") is effective as of August 1, 2021 (“Effective Date”) by and between, LAWRENCE LIN (the "EMPLOYEE"), and AINOS, INC., a Texas Corporation (the "EMPLOYER"), subject to EMPLOYER board of directors approval.
CONSULTING AGREEMENTConsulting Agreement • November 13th, 2009 • Amarillo Biosciences Inc • Pharmaceutical preparations
This Consulting Agreement (“Agreement”) is entered into as of September 4, 2009 between AMARILLO BIOSCIENCES, INC., a Texas corporation (“ABI”), and Biotech Financial, Inc. (“Consultant”), a company providing consulting services from Gary W. Coy (“Coy”).
SALES AND MARKETING AGREEMENTSales and Marketing Agreement • March 21st, 2022 • Ainos, Inc. • Pharmaceutical preparations
THIS SALES AND MARKETING AGREEMENT (“Agreement”) is made on June 14, 2021 (“Effective Date”) by and between Ainos, Inc., a Cayman Islands corporation (“Ainos KY”), and Ainos, Inc., a Texas corporation (“Ainos USA”), sometimes referred to herein, collectively as the “Parties” and individually as a “Party”.
PROMISSORY NOTE EXTENSION AGREEMENTPromissory Note Extension Agreement • August 22nd, 2023 • Ainos, Inc. • Pharmaceutical preparations
This Promissory Note Extension Agreement (the “Agreement”) is entered into this 17TH day of August, 2023 (the “Effective Date”) by and between Ainos, Inc., a Texas corporation (the “Maker”), and Ainos, Inc., a Cayman Islands corporation, or its successors or assigns (the “Holder”).
Mandate Agreement RECITALSMandate Agreement • March 17th, 2022 • Ainos, Inc. • Pharmaceutical preparations
